This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

On the way up lets hope it can hold it's gains. It went past 250 a couple of years ago so I don't think 435 is unrealistic if they have a tie up with one of the majors.

MS

GF
If you fancy a 60/40 punt have a look at FRR, Could be all or nothing.

Good News!!

Medical Marketing Int'l Group PLC
09 February 2007

Notification of Major Interests in Shares
9 February 2007

Medical Marketing International Group plc (the 'Company')(AIM:MMG), the
pharmaceutical company focused on the development of drugs for cancer and
infectious diseases, received notification on 8 February 2007 that Man Financial
Limited is interested in 3,039,200 ordinary shares of 0.2p each of the Company;
this represents 5.18% of the Company's issued share capital of 58,637,671
ordinary shares.
-ends-

Contacts
Medical Marketing International Group plc
David Best
Executive Chairman
Rob Sprawson
Chief Financial Officer
Tel: +44 (0) 1223 477 677

About MMI Group

MMI is a virtual pharmaceutical development company that identifies, acquires
and develops world-class compounds and technologies from leading academic
organizations. These technologies are aimed at producing blockbuster drugs to
satisfy unmet needs in major therapeutic markets. The company manages the
preclinical and early clinical development of drug candidates before pursuing
licensing partners to manage late-stage development. Through its three platform
technologies MMI has a risk-balanced portfolio of compounds in development for
the treatment of cancer and infectious disease. Please visit
www.mmigroup.co.uk

for further information.

Price should be up very soon.

Could we be on the move to 200. Lets hope so.

MS

Moving backwards...


Medical Marketing Int'l Group PLC
01 March 2007

Medical Marketing International Group plc
('MMI' or the 'Company')


Update for MMI's ruthenium chemotherapy portfolio

March 1st 2007. Medical Marketing International Group plc (the 'Company') (AIM:
MMG) the pharmaceutical company focused on the development of drugs for cancer
and infectious diseases, today releases a development update for its portfolio
of ruthenium-based cancer chemotherapy compounds.

A second generation of ruthenium compounds has been identified, with
those characterised showing equipotency with our existing lead candidates.
First generation compounds 4403 and 4417 on schedule for a clinical trial
application.
Further development of the first generation compound 4402 has ceased.

From MMI's patent-protected portfolio of around 8,000 ruthenium compounds, three
lead compounds for clinical development have previously been selected. In order
to better understand the relationship between the structure and activity of
ruthenium compounds, in silico modelling has been used and early results have
identified several interesting compounds that have now been synthesised and
tested in two human cancer cell lines in MMI's laboratories. These results have
shown that these two early second generation compounds have a higher cancer cell
killing ability than cisplatin, the benchmark platinum chemotherapy compound and
comparable with MMI's existing lead compounds. This raises the possibility that
compounds that are even more active may be identified during this study.

The first generation compounds, ONCO 4403 and ONCO 4417 are progressing through
the pre-clinical testing programme and are on track to enable a clinical trial
application (CTA) to be made in H2 2007. Rigorous selection of candidate
compounds is normal in pharmaceutical development and those that do not continue
to meet exacting requirements are not developed further. In line with this, the
decision has been made to discontinue the development of ONCO 4402.

David Best, Chairman of MMI said 'Our portfolio of ruthenium anti-cancer
compounds continues to show considerable promise. Two lead compounds are on
track to provide a candidate for a CTA later this year and although a third
compound has been dropped, we believe that the chemistry of ruthenium, compared
to platinum, offers considerable scope for the development of new highly potent
compounds.

This from the Prostate Cancer Charity site,

I know that some will already have seen this as it is included in a different thread. I am after as many signatures as I can generate so have started up a new topic just for this. Thanks to those who have already signed by the way.

If any one wants to sign the petition re testing it has been accepted on the Downing Street website and can be found at

http://petitions.pm.gov.uk/psa-testing/

It reads as follows


We the undersigned petition the Prime Minister to begin regular
testing for prostate cancer in men between the ages of 40 and
70

Prostate cancer is the largest cause of male deaths. A blood
test, known as PSA, can indicate that there is a problem that
needs investigating. In the Tryol district of Austria this is
being done and the mortality rates have fallen. Too many men
are being diagnosed only when it is too late for treatment to
be more than palliative.

The cancer technology of SR Pharma (SPA) is far more superior imo.

On the steep slope now...down 11p now.

Medical Marketing Int'l Group PLC
16 March 2007


Medical Marketing International Group plc

Notification of Major Interests in Shares


March 16th 2007. Medical Marketing International Group plc (the 'Company') (AIM:
MMG) the pharmaceutical company focused on the development of drugs for cancer
and infectious diseases, received notification on 15 March 2007 that as at
14 March 2007 Man Financial Limited was interested in 2,659,200 ordinary shares
of 0.2p each of the Company; this represents 4.53% of the Company's issued
share capital of 58,637,671 ordinary shares.

-ends-

Man financial.

Wonder if they have got wind of something.

Interesting.

Probably bought by Man for their spreadbetting side of the business.

No wonder the price was kicked down.

Got this from the other place, interesting.

The Real Capitalcity - 16 Mar'07 - 07:57 - 8241 of 8242


According to todays RNS, It looks like Man Financial SOLD 380,000 shares on the 14th?

A case of getting bored waiting?

I know I am! (but still holding on for now)

TRC.

Medical Marketing Int'l Group PLC
28 March 2007

Medical Marketing International Group plc

Further US patent for MMI's ruthenium cancer therapy portfolio

28th March 2007. Medical Marketing International Group plc (MMI) (AIM:MMG) the
pharmaceutical company focused on the development of drugs for cancer and
infectious diseases, today announces that it has been notified by the US Patent
and Trademark Office of the allowance of claims that further protect its
ruthenium chemotherapy portfolio. The patent will be granted following payment
of standard fees.

The 'virtual library' of ruthenium compounds protected by patents, such as the
current patent grant, now covers an extensive range of arene and ligand
chemistries, theoretically trillions of compounds, which are being evaluated
in-silico as part of the second generation program. First generation compounds
are progressing through pre-clinical testing programmes and are on track to
enable a clinical trial application (CTA) to be made in H2 2007.

David Best, Chairman of MMI Group, said 'Cytotoxics remain the mainstay of
cancer therapy, with the market for these drugs expected to achieve sales of
$12.8 billion by 2009. The further strengthening of the patent protection for
our vast ruthenium portfolio is particularly welcome as we anticipate the
clinical phase of development'.

-ends-
Contacts
Medical Marketing International Group plc Mark Burton
David Best Chief Technical Officer
Executive Chairman
Tel: +44 (0) 1223 477 677

Glad I held on to mine GF it's starting to look good. Thinking about topping up.

MS

Mickey I think we will have a good year end say around October onwards.

Sounds good to me GF. Our patience will be rewarded.

MS

agree, look at the chart, it is for sure the right moment to buy!!! I will sell other stocks even in loss and buy next week!

Malaga conference not far away now any one here attending..

Not me.

Theres too many distractions in Malaga........ hick.

Hope your doing well Mitzy.

MMGs time will come latter end of this year I believe.

Freebie from Mike Walters site....

Good News On The Way
30/3/2007 (119264)

Good News On The Way


How strange. Medical Marketing International (MMG) signals good progress towards a blockbuster DNA vaccine, and the shares actually ease 0.5p to 141p. Is everyone asleep?

Maybe the message was not simple enough. Or perhaps everyone who follows MMI knew about it anyway. Certainly it has been delivered in oblique fashion, just a short announcement drawing attention to the DNA Vaccines 2007 Conference in Malaga from May 23 to 25.

Professor Freda Stevenson of the University of Southampton will be speaking on May 23, with a presentation entitled DNA fusion gene vaccines: evolution and evaluation.

Professor Stevenson is leading the team which has made the breakthrough which appears to have made DNA vaccines a potent weapon for attacking cancer. That team is at the heart of MMIs Genvax subsidiary, and is working through clinical trials tackling a variety of cancers, supported by Cancer Research UK.

The charity funds the trials and effectively controls the release of the results. Professor Stevenson first presented results of the breakthrough at a major DNA Vaccine conference on March 18, 2005, and the stock market did not notice. Four days later, the company reported the results. After dipping below 170p, the shares began to respond, rising to 235p on the next day, and touching 300p a few days later as the full implications began to be understood. They later slumped under the weight of a malicious and ill-informed bear raid, have struggled to sustain a real recovery, and even now languish at 141p.

It appears, however, that we are about to see the next episode, and it could be exciting. While no-one knows what Professor Stevenson will say, it looks as if she will be able to release some data on the clinical trials. This will also be released to shareholders at the same time.

On May 24, Professor Stevenson will be moderator at a session which will include a presentation called DNA fusion vaccine delivery by intramuscular injection and electroporation - a well tolerated strategy for prostate cancer. This will be delivered by Dr Christian Ottensmeier, one of Professor Stevensons colleagues at Southampton, and by Dr Iacob Mathiesen, from Inovio of San Diego. Inovio is a leader in delivering genes and DNA vaccines by the electroporation process, which links injections with electric currents.

The title of this presentation clearly illustrates that the prostate cancer trials are going well, and are safe. Safety is a crucial hurdle in drug development.

It is fair to assume, then, that the May conference will bring news of important progress in the DNA vaccine trials for tackling prostate cancer, and that the results are looking good. There would be no point in presenting poor results, and while MMI is inhibited in releasing results of trials before they are complete, it would be duty bound to tell shareholders of any significant setback.

Though we will have to wait until late May for the full story, MMI is effectively indicating that it is well on the way towards establishing a DNA vaccine which can treat prostate cancer at an early stage, with a vaccine which is safe.

That is potentially very big news. We know that some DNA vaccines have to be tailored to each individual patient, opening a viable but less attractive market. The prostate cancer vaccine is generic one variety fits all and addresses a massive market. And if the vaccines succeed against prostate cancer, that adds credibility to other varieties being developed to tackle different cancers.

This underlines the potential of MMI. Currently capitalised at around 82m, it has the Genvax (51% owned but on the way to 58%) subsidiary with five phase two cancer vaccine trials in progress, ruthenium due to enter the clinic later this year, and a promising ribozyme project, all for spending of some 11m by the company.

There are discussions with virtually all of the leading pharmaceutical companies, and any one of these three areas could develop into a blockbuster - though any or all could fail, given the nature of this business.

It is frustrating that the share price is well below the level it reached two years ago, but the company has moved considerably further along in raising potential value. A high proportion of the shares is held by institutions who understand and believe in the story.

As ever, MMI looks an outstanding gamble. And as the significance of the May conference begins to filter through to the market, we could see useful action.

I have a holding in Medical Marketing.

Ends